ESC 365 - Use of aspirin and impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation: an analysis from the SPORTIF trials

ESC Premium Access

Use of aspirin and impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation: an analysis from the SPORTIF trials

Session: How to make oral anticoagulation safe

Topic: Drug therapy

Speaker: Associate Professor M. Proietti (Milan, IT)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Associate Professor Marco Proietti

University of Milan, Milan (Italy)

11 presentations

1 follower

4 more presentations in this session

State of the Art: oral anticoagulation in the challenging patient

Speaker: Professor P. Kirchhof (Hamburg, DE)

Increased bleeding events in patients co-administered rivaroxaban and either cyp3A4 or p-gp inhibitors

Speaker: Doctor J. Michel (Austin, US)

Clinical determinants of time in therapeutic range and the role of SAMe-TT2R2 score in atrial fibrillation patients receiving oral anticoagulation: data from FANTASIIA registry.

Speaker: Doctor M. Esteve Pastor (Murcia, ES)

The future of oral anticoagulation

Speaker: Doctor J. Weitz (Hamilton, CA)

Access the full session

How to make oral anticoagulation safe

Speakers: Associate Professor M. Proietti, Professor P. Kirchhof, Doctor J. Michel, Doctor M. Esteve Pastor, Doctor J. Weitz

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources